U.S. markets closed
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • Dow 30

    34,347.03
    +152.97 (+0.45%)
     
  • Nasdaq

    11,226.36
    -58.96 (-0.52%)
     
  • Russell 2000

    1,869.19
    +5.67 (+0.30%)
     
  • Crude Oil

    76.28
    -1.66 (-2.13%)
     
  • Gold

    1,754.00
    +8.40 (+0.48%)
     
  • Silver

    21.43
    +0.06 (+0.29%)
     
  • EUR/USD

    1.0405
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    3.6910
    -0.0150 (-0.40%)
     
  • GBP/USD

    1.2091
    -0.0023 (-0.19%)
     
  • USD/JPY

    139.1000
    +0.5100 (+0.37%)
     
  • BTC-USD

    16,596.31
    +98.99 (+0.60%)
     
  • CMC Crypto 200

    386.97
    +4.32 (+1.13%)
     
  • FTSE 100

    7,486.67
    +20.07 (+0.27%)
     
  • Nikkei 225

    28,283.03
    -100.06 (-0.35%)
     

Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation

  • Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has announced the presentation of new safety and efficacy data of roflumilast foam to treat scalp and body psoriasis.

  • Data were presented in a late-breaking oral presentation at the American Academy of Dermatology Virtual Meeting Experience.

  • New findings demonstrate that roflumilast foam significantly improved both scalp and body psoriasis, with improvement as early as two weeks after treatment initiation.

  • The primary endpoint of the clear or almost clear scalp at week eight was achieved by 59.1% of patients receiving roflumilast foam versus 11.4% of patients receiving vehicle.

  • 34.3% of roflumilast foam-treated and 3.4% of vehicle-treated patients rated clear at week eight.

  • Clear or almost clear on the body at week eight was achieved by 40.3% and 6.8% of patients receiving roflumilast foam and vehicle, respectively.

  • The most common treatment-related adverse events were application site pain (1.0% vs. 3.8%), diarrhea (1.5% vs. 0%), COVID-19 (1.5% vs. 1.9%), sinusitis (0.5% vs. 1.9%), psoriasis (0.5% vs. 1.9%), and hypertension (1.5% vs. 1.0%) for roflumilast foam and vehicle, respectively.

  • Discontinuation due to adverse events was 2.5% for roflumilast foam and 1.9% for the vehicle. In the study, no patients in either group experienced any serious adverse events.

  • Additionally, findings from Phase 2 study of Roflumilast Foam 0.3% in seborrheic dermatitis demonstrated roflumilast foam is a safe, well-tolerated, and effective treatment.

  • Treatment with roflumilast foam led to significant improvement in skin clearance and erythema and scaling individually and symptomatic improvement in itch in patients.

  • In the psoriasis Phase 2b study, roflumilast cream was well-tolerated. It provided significant improvements in investigator and patient‑assessed outcomes in participants with steroid-sensitive area involvement in a post-hoc analysis of the face, neck, or intertriginous areas in patients with chronic plaque psoriasis.

  • Roflumilast Cream and Foam are once-daily, topical formulations of a highly potent and selective PDE4 inhibitor.

  • Price Action: ARQT shares are down 3.4% at $29.53 in market trading hours on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.